Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Jasper Therapeutics, Inc. (JSPR) had Normalized Income after Taxes of $-18.74M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-18.74M |
|
-- |
|
-- |
|
$19.17M |
|
$-19.17M |
|
$0.43M |
|
$-18.74M |
|
$-18.74M |
|
$-18.74M |
|
$-18.74M |
|
$-18.74M |
|
|
Normalized Income after Taxes |
$-18.74M |
$-19.17M |
|
$-18.94M |
|
16.64M |
|
16.64M |
|
$-1.13 |
|
$-1.13 |
|
| Balance Sheet Financials | |
$54.56M |
|
$1.10M |
|
$2.90M |
|
$57.47M |
|
$21.04M |
|
-- |
|
$24.86M |
|
$45.90M |
|
$11.57M |
|
$11.57M |
|
$11.57M |
|
27.98M |
|
| Cash Flow Statement Financials | |
$-55.29M |
|
$0.01M |
|
$34.55M |
|
$72.05M |
|
$51.32M |
|
$-20.74M |
|
$5.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.59 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-55.29M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-161.92% |
|
-161.92% |
|
-32.60% |
|
-161.92% |
|
$0.41 |
|
$-3.32 |
|
$-3.32 |
|